| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alaunos Therapeutics, Inc.$2.05
+0.01 (+0.48%)
D 27Pipeline Score Overvalued Biotech · Clinical
Market Cap
59.10 M
EPS
-2.17
P/E Ratio
-
Value Trade
86.31 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
427.00 K
Operating CF
-1.03 M
Total Assets
1.88 M
Total Liabilities
595.00 K
Equity
1.29 M
D/E Ratio
12,345
-5.47 %
Week
-13.26 %
1 Month
-4.72 %
3 Month
-29.45 %
6 Month
-99.49 %
5 Year
-99.73 %
All Time
Cash Data
Cash Position
354.00 K
Monthly Burn
344.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
10.71 K
52 Week Range
1.67 - 6.20
% held by Insiders
16.34 %
% held by Institutions
5.16 %
Enterprise Value
58.75 M
Total Shares
2.40 M
Short %
0.57 %
Float Shares
1.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alaunos Therapeutics, Inc.
621Total events
3Upcoming
93Tier-1 (high impact)
2009 – 2026Coverage
Upcoming catalysts 3
Event history 618
May 26, 2026
▲Preclinical PoCALN1003Preclinical
Integrated preclinical readout for ALN1003 in DIO mouse studies
obesity and related metabolic disorderssource ↗
May 26, 2026
●Oral PresentationALN1003Presentation
Investor presentation published with integrated preclinical data
obesity and related metabolic disorderssource ↗
May 18, 2026
▲Preclinical PoCALN1003Preclinical
Preclinical data for ALN1003 in DIO mouse models showing effects on insulin-resistance-related biomarkers and liver histology
metabolic syndromesource ↗
May 18, 2026
▼Runway Guidance UpdateCorporate
Cash runway extends into Q2 2026; company intends to pursue additional financing
Mar 2, 2026
▲Preclinical PoCALN1003Preclinical
Positive preclinical proof-of-concept data for ALN1003 in DIO mouse models
obesity and related metabolic disorderssource ↗
Jun 23, 2025
▼Equity OfferingCorporate
Registered direct offering of 610,399 shares at $3.36 per share for gross proceeds of $2.0 million
Drug Pipeline Intelligence
D27
Pipeline Score $16M
Pipeline ValueOvervalued
Valuation Signal10
Drugs Scored0.3x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankAlaunos Therapeutics, Inc. faces pipeline headwinds (27/100), with $1.5B risk-adjusted pipeline value, led by Darinaparsin in Hematologic Neoplasms (Phase 2), across $94B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Darinaparsin Small molecule | Hematologic Neoplasms | Phase 2 | NCT00421213 | 10% | $612M | COMPLETED | 50 | - | - | Apr 1, 2012 | - | Jul 19, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ALN1003 | obesity and related metabolic disorders | — | 2026-03-02 | body weight change: -12.9% (p<0.0001) on Day 34; body weight change 48 days: -10.3% (p<0.0001); food consumption: 347.5 g/cage vs 425.0 g/cage; nominal p<0.05; liver weight reduction: 43% (p<0.0001); liver weight percentage change: 39% (p<0.0001); ALT reduction: lower ALT (p<0.0001); AST reduction: lower AST (nominal p<0.0001); ALP reduction: lower ALP (p<0.0001); total bilirubin trend: nominal p=0.058 Read More | Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders Read More | |
ALN1003 | obesity and related metabolic disorders | — | 2026-03-02 | body weight change: -12.9% (p<0.0001) on Day 34; body weight change 48 days: -10.3% (p<0.0001); food consumption: 347.5 g/cage vs 425.0 g/cage; nominal p<0.05; liver weight reduction: 43% (p<0.0001); liver weight percentage change: 39% (p<0.0001); ALT reduction: lower ALT (p<0.0001); AST reduction: lower AST (nominal p<0.0001); ALP reduction: lower ALP (p<0.0001); total bilirubin trend: nominal p=0.058 Read More | Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders Read More | |
ALN1003 | obesity and related metabolic disorders | — | 2026-03-02 | body weight change: -12.9% (p<0.0001) on Day 34; body weight change 48 days: -10.3% (p<0.0001); food consumption: 347.5 g/cage vs 425.0 g/cage; nominal p<0.05; liver weight reduction: 43% (p<0.0001); liver weight percentage change: 39% (p<0.0001); ALT reduction: lower ALT (p<0.0001); AST reduction: lower AST (nominal p<0.0001); ALP reduction: lower ALP (p<0.0001); total bilirubin trend: nominal p=0.058 Read More | Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TCRT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TCRT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TCRTAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies • ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight an
Alaunos Therapeutics announced the positive findings of its investigational drug ALN1003 in recent preclinical studies involving diet-induced obese mice. The data indicated substantial improvements in metabolic parameters, such as body weight reduction, enhanced insulin sensitivity, and improved liver health. Additionally, the company released a non-confidential investor presentation detailing these results and their implications for future therapeutic approaches. Despite the promising results, the studies were non-GLP, which necessitates careful interpretation of the findings.
Read more →TCRTAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Alaunos Therapeutics announced preclinical data showing that ALN1003, an investigational oral therapeutic candidate, positively affects insulin-resistance-related biomarkers and liver histology in diet-induced obesity mouse models. Key findings include significantly lower fasting insulin levels and improvements in adipose endocrine markers. These results support ALN1003's continued development as a potential treatment for metabolic syndrome and related conditions. However, the data comes from preclinical studies, emphasizing the need for caution as human trials have not yet been conducted.
Read more →TCRTAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models Findings from non-GLP DIO mouse studies show effe
Alaunos Therapeutics announced promising results from preclinical studies of ALN1003, an investigational oral metabolic therapeutic for obesity and metabolic syndrome. The treatment demonstrated positive effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity mouse models. Although these findings support further research, the company acknowledges the early-stage nature of the data and the need for caution due to limitations in the study. Alaunos plans to advance ALN1003 through additional preclinical studies to explore its full therapeutic potential.
Read more →TCRTAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
Alaunos Therapeutics announced promising preclinical data for ALN1003, a non-hormonal oral treatment for obesity. In diet-induced obesity mouse models, ALN1003 demonstrated significant body weight loss and favorable changes in liver health. The company plans to continue preclinical studies and refine manufacturing processes as it moves toward an Investigational New Drug application.
Read more →TCRTAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering
Alaunos Therapeutics announced a registered direct offering of 610,399 shares at $3.36 each, aiming to raise approximately $2 million. The net proceeds will be allocated to its obesity program and general corporate needs. The transaction is expected to close on June 24, 2025, pending customary conditions. This offering is part of a previously filed shelf registration statement.
Read more →TCRT▼ -10.6%on this news
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos Therapeutics reported its third quarter 2023 financial results, highlighting the exploration of strategic alternatives and the outcomes of its TCR-T Library Phase 1/2 Trial. The trial demonstrated that the T cells were well-tolerated, with one patient achieving a partial response. However, the company announced it would halt further clinical program development due to high costs and a challenging financing environment.
Read more →TCRTAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable pa
Alaunos Therapeutics reported its financial results for Q2 2023 along with interim clinical data and strategic changes. The company achieved an 83% disease control rate in its TCR-T Library Phase 1/2 trial, although it is winding down this trial to focus on its hunTR TCR discovery platform. A significant workforce reduction of approximately 60% has been announced as part of a cost-saving strategy, while strategic alternatives for the company are being explored, including potential partnerships or acquisitions. Overall, Alaunos aims to reposition itself for future developments despite current challenges.
Read more →TCRT▲ +14.3%on this news
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
Alaunos Therapeutics announced its participation in the 2nd Hawaii Global Summit on Thoracic Malignancies, where Dr. Matthew Collinson-Pautz will present on their TCR-T therapy targeting specific mutations in solid tumors. The therapy is currently being evaluated in a Phase 1/2 trial at MD Anderson Cancer Center, focusing on various cancers with specific driver mutations. This summit aims to address advancements in lung cancer treatment.
Read more →TCRT▼ -16.6%on this news
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
Alaunos Therapeutics announced it will present early data from its TCR-T Library Phase 1/2 trial at the 2023 ASCO Annual Meeting. The trial has shown promising results, including objective clinical responses in two patients with solid tumors. The therapy demonstrated a favorable safety profile, with no significant toxicities reported. The company plans to provide further updates in the third quarter of 2023.
Read more →TCRTAlaunos Therapeutics Reports First Quarter 2023 Financial Results Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter
Alaunos Therapeutics reported its financial results for Q1 2023 and highlighted the ongoing patient enrollment in its TCR-T Library Phase 1/2 trial, focusing on solid tumor indications. The company anticipates interim data to be shared in Q3 2023 and is enhancing its manufacturing capabilities for better flexibility in patient scheduling. A significant financial step was taken with the prepayment of a loan to Silicon Valley Bank, allowing operations to proceed without debt constraints. However, the company also faced a net loss of $10 million for the quarter, raising concerns about its financial outlook.
Read more →TCRTAlaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
Alaunos Therapeutics has announced it will report its financial results for the first quarter of 2023 on May 10, 2023. The report will be followed by a conference call aimed at discussing the results and providing corporate updates. The company is recognized for its innovative work in T-cell receptor cell therapy, particularly in targeting solid tumors through advanced clinical trials.
Read more →TCRT▲ +10%on this news· ran to +22% by day 3
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Alaunos Therapeutics announced a poster presentation at the 2023 ASCO Annual Meeting for its lead TCR-T cell therapy program. The Phase 1/2 trial focuses on patients with specific solid tumors and targeted mutations. The presentation will take place on June 3, 2023, showcasing the safety and efficacy of their innovative therapy.
Read more →TCRTAlaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
Alaunos Therapeutics has appointed Dr. Robert J. Hofmeister to its Board of Directors, replacing Chris Bowden. Dr. Hofmeister, who has extensive experience in T-cell receptor therapies, aims to leverage his expertise to enhance Alaunos' TCR-T Library Phase 1/2 trial. The company is focused on revolutionizing solid tumor treatments.
Read more →TCRTAlaunos Therapeutics to Participate in Upcoming Investor Conferences in April
Alaunos Therapeutics announced its participation in two upcoming investor conferences in April 2023. The events include Cantor's The Future of Oncology Virtual Symposium on April 4 and the 22nd Annual Needham Virtual Healthcare Conference on April 17. The company aims to showcase its advancements in T-cell receptor therapy for solid tumors during these presentations.
Read more →TCRTAlaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvi
Alaunos Therapeutics reported its fourth quarter and full year 2022 financial results, highlighting significant advancements in its TCR-T cell therapies. The company has seen positive clinical data and is actively enrolling patients in its TCR-T Library Phase 1/2 trial, expecting to report interim data soon. Alaunos has also made enhancements to its TCR library and manufacturing processes, aiming to optimize production and increase patient enrollment. Despite these advancements, the company reported a net loss of $9.2 million for the fourth quarter, reflecting some financial challenges amidst growth efforts.
Read more →TCRTAlaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company, announced it will report its financial results for the fourth quarter and full year ended December 31, 2022, on March 7, 2023. Alongside the financial report, the company will hold a conference call to provide a corporate update, reinforcing its commitment to investor engagement. Alaunos is at the forefront of T-cell receptor therapy, actively working to improve cancer treatment outcomes through advanced TCR programs.
Read more →TCRTAlaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
Alaunos Therapeutics has outlined its strategic priorities and anticipated milestones for 2023, highlighting the addition of two new T cell receptors (TCRs) to its library, which is expected to double its addressable market. The company aims to increase patient enrollment in its TCR-T Library Program to advance to Phase 2 and improve manufacturing capabilities for greater efficiency. Additionally, Alaunos is planning to file for an Investigational New Drug (IND) for its mbIL-15 therapy later this year. With a solid cash position, the company is well-prepared for its strategic initiatives.
Read more →TCRTAttacking Solid Tumors with Novel TCR-T Cell Therapies January 2023 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as
Alaunos Therapeutics is focusing on novel TCR-T cell therapies aimed at treating solid tumors, with significant accomplishments anticipated in the pipeline. Key developments include expanding their TCR library and achieving promising preliminary clinical outcomes. However, the firm also faces uncertainties related to capital raising and achieving regulatory approvals, which could affect their research and development trajectory. The data provided highlights both the potential of their therapies and the numerous risks involved in their clinical programs.
Read more →TCRT▼ -22.8%on this news
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its com
Read more →TCRT▼ -5.8%on this news· ran to -31% by day 3shared move
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an
Read more →TCRT▼ -6.5%on this news
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the C
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results HOUSTON, November 14, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the third quarter ende
Read more →TCRTAlaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. F
Read more →TCRTAlaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting Data supports high-throughput screening process to identify neoantigen-rea
Alaunos Therapeutics to Present Data Highlighting its Platform at the Society for Immunotherapy of Cancer HOUSTON, November 7, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a po
Read more →TCRTObjective clinical response by KRAS mutation- specific TCR-T cell therapy in previously treated advanced non-small cell lung cancer Marcelo V. Negrao, MD Assistant Professor Department of Thoracic / Head and Neck Medical
TCR-T cell therapy in previously treated advanced non-small cell lung cancer Marcelo V. Negrao, MD Assistant Professor Department of Thoracic / Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center Forward Looking Statements Disclaimer This presentation co
Read more →TCRTAlaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference First patient achieved a confirmed partial response with 51.2% tumor regres
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference 21, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today annou
Read more →TCRTAlaunos Therapeutics to Participate in Upcoming Investor Conferences in September
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Researc
Read more →TCRTAlaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy September 6, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced ear
Read more →TCRTAlaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference HOUSTON, August 24 , 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage on
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference HOUSTON, August 24, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that
Read more →TCRTAlaunos Therapeutics Reports Second Quarter 2022 Financial Results Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results HOUSTON, August 15, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the second quarter ende
Read more →TCRTAlaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open of U.S. markets. Followi
Read more →TCRTAlaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations HOUSTON, August 04 , 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-f
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations HOUSTON, August 04, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointmen
Read more →TCRT▲ +17.3%on this news· ran to +32% by day 3
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies To 2025 NCI will lead the Company s personalized TCR-T cel
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies To 2025 HOUSTON, June 27, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-sta
Read more →TCRT▼ -8.6%on this news
Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Rese
Read more →TCRTAlaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annu
Read more →TCRTH.C. Wainwright Global Investment Conference
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms
Read more →TCRT▼ -15.2%on this news
Alaunos Therapeutics Reports First Quarter 2022 Financial Results Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present
Alaunos Therapeutics Reports First Quarter 2022 Financial Results Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25th Annual Meeting h
Read more →TCRT▲ +6.2%on this news· ran to -19% by day 1
Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Resea
Read more →TCRTAlaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following t
Read more →TCRT▼ -7.3%on this news· ran to +18% by day 3
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors First-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers Fi
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors HOUSTON, May 2, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today ann
Read more →TCRT▼ -7.3%on this news· ran to +18% by day 3
Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutatio
Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy HOUSTON, May 2, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the
Read more →TCRTAlaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is ex
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results HOUSTON, March 30, 2022 Alaunos Therapeutics, Inc. ( Alaunos or the Company ) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the fourth
Read more →TCRT▲ +10.1%on this news
Attacking Solid Tumors with Novel TCR-T Cell Therapies Oppenheimer 32nd Annual Healthcare Conference March 2022 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private S
Oppenheimer 32nd Annual Healthcare Conference March 2022 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not hist
Read more →TCRT▲ +8.4%on this news· ran to +19% by day 1shared move
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open of U.S. markets.
Read more →TCRTAlaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company’s Chief Executive Officer, Kevin S. Boyle Sr., and Vice President of Resear
Read more →TCRTAttacking Solid Tumors with Novel TCR-T Cell Therapies January 2022 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms
Read more →TCRTZiopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway  Over 50% reduction in personnel  Cost reductions expected to extend the cash runway into the first half of 2023 &
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway Over 50% reduction in personnel Cost reductions expected to extend the cash runway into the first half of 2023 The first patient in its TCR-T Library Phase I/II clinical trial is expected
Read more →TCRTZiopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership r
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creati
Read more →TCRTZiopharm Oncology Provides Second Quarter 2021 Corporate Updates Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company s manufacturing facility and presentation of favora
Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company s manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with S
Read more →TCRTZiopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting Highlighted distinctive cellular therapy program, market opportunity and value proposition Shared optimistic outlook
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting Highlighted distinctive cellular therapy program, market opportunity and value proposition Shared optimistic outlook and commitment to deliver value to shareholders Encourage
Read more →TCRTZiopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates Annual shareholder meeting planned for
Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates Annual shareholder meeting planned for May 19, 2021 Company to host conference call today at 4:30 pm ET Boston, May 6, 2021 Ziopharm Oncology, Inc. ( Ziopharm or the Company ) (Nasdaq
Read more →TCRTZiopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Per
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Con
Read more →TCRTZiopharm Oncology Announces Election of Robert Postma to its Board of Directors Boston
Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors Boston, February 5, 2021 Ziopharm Oncology, Inc. ( Ziopharm or the Company ) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the Board ), effective immediately
Read more →TCRTForward Looking Statements This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the P
J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 Exhibit 99.1 Forward Looking Statements This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements
Read more →TCRTZIOPHARM COMMENTS ON CONSENT SOLICITATION RESULTS Jaime Vieser and Holger Weis Elected to Board of Directors; Scott Tarriff Departs Board BOSTON
COMMENTS ON CONSENT SOLICITATION RESULTS Vieser and Holger Weis Elected to Board of Directors; Scott Tarriff Departs Board December 16, 2020 - Ziopharm Oncology, Inc. (Nasdaq: ZIOP) ("Ziopharm" or the "Company"), today issued a statement in connection with the consent solicita
Read more →TCRTZiopharm Oncology Announces Chief Financial Officer to Step Down BOSTON
Ziopharm Oncology Announces Chief Financial Officer to Step Down BOSTON, December 14, 2020 Ziopharm Oncology, Inc. (Nasdaq: ZIOP) ( Ziopharm or the Company ), today announced that Satyavrat Sath Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to
Read more →TCRTZiopharm Oncology Appoints Mary Thistle to Board of Directors - Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director - - Biotechnology Leader wit
Ziopharm Oncology Appoints Mary Thistle to Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director - Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercia
Read more →TCRTZiopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library hotspot trial Eden BioCell on track for
Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library hotspot trial Eden BioCell on track for IND filing in Taiwan for autologus CAR-T clinical trial t
Read more →TCRTZiopharm Oncology Appoints Kevin Buchi to its Board of Directors Life Sciences industry veteran; 15-year Cephalon executive, serving progressively as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva Doug
Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors Life Sciences industry veteran; 15-year Cephalon executive, serving progressively as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva Doug Pag n Steps Down from Board of Directors Boston, Septem
Read more →TCRTZiopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron s Libtayo First patient with DIPG dosed in phas
Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron s Libtayo First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 Wor
Read more →TCRTZiopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology Longer term follow-up from Controlled IL-12 monother
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survi
Read more →TCRTZiopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update Regulatory discussions with FDA advance Ziopharm TCR-T IND process Enrollment on track in Controlled IL-12 phase 2 clinical tri
Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update Regulatory discussions with FDA advance Ziopharm TCR-T IND process Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron s Libtayo ; Controlled IL-12 clinical
Read more →TCRTZiopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019 Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 Balance sheet strengthened; cash of approximately $177 m
Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019 Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 Balance sheet strengthened; cash of approximately $177 million funds operations to Clinical trial milestones and
Read more →TCRTZiopharm Oncology Announces Pricing of Public Offering of Common Stock BOSTON, MA
Ziopharm Oncology Announces Pricing of Public Offering of Common Stock BOSTON, MA Feb. 5, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering pri
Read more →TCRTZiopharm Oncology Announces Proposed Public Offering of Common Stock BOSTON, MA
Ziopharm Oncology Announces Proposed Public Offering of Common Stock BOSTON, MA Feb. 4, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of
Read more →TCRTZiopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting Controlled IL-12 evaluated as monotherapy in an
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety
Read more →TCRTZiopharm Oncology Reports Third Quarter 2019 Financial Results Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) New agreement with MD And
Ziopharm Oncology Reports Third Quarter 2019 Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting
Read more →TCRTZiopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots E
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots Enables two new TCR-T clinical trials at MD Anderson lev
Read more →TCRTZiopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm s Slee
Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm s Sleeping Beauty platform Rapid personalized manufacture of C
Read more →TCRTZiopharm Oncology Reports Second Quarter 2019 Financial Results FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors at the National Cancer Institute (NCI) Exclusive lice
Ziopharm Oncology Reports Second Quarter 2019 FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors at the National Cancer Institute (NCI) Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens i
Read more →TCRTZiopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration Boston
Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration Boston, July 29, 2019 Ziopharm Oncology, Inc. ( Ziopharm ) (Nasdaq:
Read more →TCRTZiopharm Oncology Names NCI s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program Dr. Deniger joins from National Cancer Institute to lead Ziopharm s non-viral T-cell program targeting neoantigens for personalized immu
Ziopharm Oncology Names NCI s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program Dr. Deniger joins from National Cancer Institute to lead Ziopharm s non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors July 3, 2019 Ziopharm Oncology,
Read more →TCRTZiopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma Phase 2 trial will enroll approximately 30 patient
Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with (cemiplimab-rwlc) to Treat Patients with Recurrent Phase 2 trial will enroll approximately 30 patients and evaluate both BOSTON, June 27, 2019 Ziopharm Oncology, Inc. ( Ziopharm
Read more →TCRTZiopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo (nivolumab) Phase 1 Combination Trial in Brain Cancer Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals
Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo (nivolumab) Phase 1 Combination Trial in Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study BOSTON, Ju
Read more →TCRTZiopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines - Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin at NCI in mid-2019 - Third-gen
Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines - Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 -
Read more →TCRTZiopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - Phase 1 Trial of Sleeping Beauty -TCR-T cell therapy for patients with solid tumors to begin at National Cance
Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate - Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 Sleeping Beauty CD19-specific CAR-T U.S.
Read more →TCRTForward Looking Statement This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Pr
Ziopharm ONCOLOGY 37th Annual J.P. Morgan Healthcare Conference January 2019 Exhibit 99.1 Forward Looking Statement This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looki
Read more →TCRTZiopharm Oncology Posts Letter to Stockholders BOSTON, MA
Ziopharm Oncology Posts Letter to Stockholders BOSTON, MA, Jan. 7, 2019 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37th Annual J.P. Morgan Healthcare Conference upon us, we wanted to
Read more →TCRTZiopharm Oncology Announces $50 Million Private Placement BOSTON
Ziopharm Oncology Announces $50 Million Private Placement BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to purchase
Read more →TCRTZiopharm Oncology Announces Changes to Board of Directors and Management Team - CEO Laurence Cooper Appointed to Board of Directors - Francois Lebel to Depart Company BOSTON
Ziopharm Oncology Announces Changes to Board of Directors and Management Team - CEO Laurence Cooper Appointed to Board of Directors - Francois Lebel to Depart Company BOSTON, October 16, 2018 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focus
Read more →TCRTZiopharm and Precigen Redefine Relationships, Announce New License Agreement Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, MD
Ziopharm and Precigen Redefine Relationships, Announce New License Agreement Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, MD, October 9, 2018 Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (Nas
Read more →TCRTZiopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Company Focused on Responding to FDA for Third-generation Trial - NCI to file IND for Sleeping Beauty Manufactured TCR-T Cel
Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Company Focused on Responding to FDA for Third-generation Trial - NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens - Controlled IL-12 Mon
Read more →TCRTZiopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy BOSTON
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy BOSTON, June 18, 2018 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration (FDA) placed
Read more →TCRTZiopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update - Expanding Controlled IL-12 platform to explore additional tumor types - Cash runway extended to 2Q 2019 with changes to Contr
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update - Expanding Controlled IL-12 platform to explore additional tumor types - Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans - ASCO poster to detail IL-
Read more →TCRTZiopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - Company to host conference call today at 4:30 p.m.
Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate - Company to host conference call today at 4:30 p.m. ET BOSTON, MA March 1, 2018 Ziopharm Oncology, Inc. (Nasdaq: ZIOP), a biotechnology company focused on development of next
Read more →TCRTZiopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance BOSTON, MA
Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance BOSTON, MA February 6, 2018 Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no develop
Read more →TCRTThis presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigatio
The Next Generation of Immunotherapy Platforms 36th Annual J.P. Morgan Healthcare Conference January 2018 Exhibit 99.1 This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-lo
Read more →TCRTZiopharm Oncology Provides Update on Standout Technologies during the 36 th Annual J.P. Morgan Healthcare Conference - Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO (nivolumab)
Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference - Controlled IL-12 advancing as drug platform as monotherapy and in combination with - Non-viral T-cell platform shows potential for efficacy, scalability and c
Read more →TCRTZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities - Company to host conference call today at 4:30 p.m. ET - Pivotal, randomized control trial in rGBM to initiate by e
ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities - Company to host conference call today at 4:30 p.m. ET - Pivotal, randomized control trial in rGBM to initiate by end of 2017 - - Combination trial with checkpoint inhibito
Read more →TCRTZIOPHARM Oncology Appoints David Mauney, M.D., as EVP and Chief Business Officer BOSTON, MA
ZIOPHARM Oncology Appoints David Mauney, M.D., as EVP and Chief Business BOSTON, MA Sept. 28, 2017 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President an
Read more →TCRTZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON
ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON, July 31, 2017 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new immunoth
Read more →TCRTZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting Median Overall Survival in Expanded 20 mg Cohort Maintained at 12.5 Months and C
ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting Median Overall Survival in Expanded 20 mg Cohort Maintained at 12.5 Months and Continues to Compare Favorably to Historical Controls Impac
Read more →TCRTZIOPHARM ONCOLOGY ANNOUNCES PRICING OF $50 MILLION FOLLOW-ON
ZIOPHARM ONCOLOGY ANNOUNCES PRICING OF $50 MILLION FOLLOW-ON OFFERING OF COMMON STOCK BOSTON, May 12, 2017 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it has priced an underwritten follow-on offering
Read more →TCRTZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia Phase 1 Study Expected to Initiate in Third Quarter 2017 BOSTON
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia Phase 1 Study Expected to Initiate in Third Quarter 2017 BOSTON, May 2, 2017 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company foc
Read more →TCRTZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer - Co
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer Company to Host Conference Call Today at 4:30 p.m. ET - BOSTO
Read more →TCRTZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma BOSTON, MA
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma BOSTON, MA March 27, 2017 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of
Read more →TCRTZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities - Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference - BOSTON, MA
ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities - Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference - BOSTON, MA February 16, 2017 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a bi
Read more →TCRTZIOPHARM ONCOLOGY 35th Annual J.P. Morgan Healthcare Conference
Healthcare Conference This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995, as amended. Forw
Read more →TCRTZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens BOSTON, MA and GERMANTOWN, MD
ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens BOSTON, MA and GERMANTOWN, MD January 10, 2017 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a b
Read more →TCRTZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer Data to Be Presented at the 21 st Society for Neuro-Oncology Annual Meeting Non-clinical Study Supp
ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer Data to Be Presented at the 21st Society for Neuro-Oncology Annual Meeting Non-clinical Study Supports Initiation of New Clinical Trial of Ad-RTS-hIL-12 in
Read more →TCRTZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities Company to Host Conference Call on Thursday
ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities Company to Host Conference Call on Thursday, November 17, 2016 at 8:00 am ET to Discuss Updated Data from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Brain Cancer Presented at SNO 2
Read more →TCRTZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities - Company to Host Conference Call at 4:30 PM ET Today - BOSTON, MA
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities - Company to Host Conference Call at 4:30 PM ET Today - BOSTON, MA August 9, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the second quarter en
Read more →TCRTZIOPHARM Issues Statement Clarifying Speculation on Financing Activity BOSTON, MA
ZIOPHARM Issues Statement Clarifying Speculation on Financing Activity BOSTON, MA July 20, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), due to recent developments, today issued the following statement clarifying market speculation regarding the Company s financing activity: Th
Read more →TCRTZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer BOSTON, MA
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer BOSTON, MA July 19, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today provided an update regarding the Company s ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally
Read more →TCRTZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer BOSTON, MA
ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer BOSTON, MA July 15, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today issued the following statement regarding the Company s ongoing multicenter Phase 1 study of Ad-RTS-hI
Read more →TCRTIntrexon and ZIOPHARM Amend Exclusive Channel Collaborations to Improve Alignment as Programs Advance through Development Germantown, MD, and Boston, MA
Intrexon and ZIOPHARM Amend Exclusive Channel Collaborations to Improve Alignment as Programs Advance Germantown, MD, and Boston, MA June 30, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical co
Read more →TCRTZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer BOSTON, MA
ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer MA June 27, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new cancer i
Read more →TCRTZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer Data to be Presented at the 2016 ASCO Annual Meeting Company to Discuss Results w
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer Data to be Presented at the 2016 ASCO Annual Meeting Company to Discuss Results with Regulators after Additional Follow Up BOSTON, MA May
Read more →TCRTZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities BOSTON, MA
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities BOSTON, MA May 10, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company s r
Read more →TCRTZIOPHARM Jefferies Immuno-Oncology Summit April 2016 Forward-looking statements This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harb
Jefferies Immuno-Oncology Summit Forward-looking statements contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 19
Read more →TCRTZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities BOSTON, MA
ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities BOSTON, MA February 24, 2016 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the fourth quarter ended December 31, 2015, and provided an update on the c
Read more →TCRTZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase 1 Study of Ad-RTS-hIL-12 for Advanced Glioma BOSTON, MA
ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase 1 Study of Ad-RTS-hIL-12 for Advanced Glioma BOSTON, MA February 24, 2016 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announ
Read more →TCRTZIOPHARM 34th Annual J.P. Morgan Healthcare Conference January 2016 ZIOPHARM Oncology Forward-looking statements This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intend
ZIOPHARM 34th Annual J.P. Morgan Healthcare Conference January 2016 ZIOPHARM Oncology Forward-looking statements This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward-looking st
Read more →TCRTZIOPHARM Announces Presentation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients with Locally Advanced or Metastatic Breast Cancer at 2015
ZIOPHARM Announces Presentation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients with Locally Advanced or Metastatic Breast Cancer at 2015 SABCS BOSTON, MA December 10, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new cancer
Read more →TCRTZIOPHARM Announces Presentation of Data from CD19-Specific CAR + T-Cell Therapy Programs at ASH Annual Meeting Results demonstrate survival benefit in long-term follow-up infusing autologous genetically modified T cells
ZIOPHARM Announces Presentation of Data from CD19-Specific CAR+ T-Cell Therapy Programs at ASH Annual Meeting Results demonstrate survival benefit in long-term follow-up infusing autologous genetically modified T cells after HSCT Results demonstrate survival benefit in follow
Read more →TCRTZIOPHARM Announces Data Highlighting Ad-RTS-hIL-12 Activity in Glioma at SNO Early Clinical Results Find Veledimex Crosses Blood Brain Barrier, Ad-RTS-hIL-12 Activation in Tumor Results in IL-12 in Peripheral Blood, Trea
ZIOPHARM Announces Data Highlighting Ad-RTS-hIL-12 Activity in Glioma at SNO Early Clinical Results Find Veledimex Crosses Blood Brain Barrier, Ad-RTS-hIL-12 Activation in Tumor Results in IL-12 in Peripheral Blood, Treatment Is Well Tolerated with Minimal Neurologic Toxicity
Read more →TCRTSynthetic Biology Leads to Powerful Engineering of Immune System Immune cells are capable of preventing and eliminating disease Yet the body's own programming language governing an immune response is unable to eliminate
Harnessing the power of the immune system to fight cancer Laurence Cooper M.D., Ph.D. Chief Executive Officer, ZIOPHARM Oncology, Inc. Exhibit 99.1 Synthetic Biology Leads to Powerful Engineering of Immune System Immune cells are capable of preventing and eliminating disease Y
Read more →TCRTZIOPHARM Reports Third-Quarter 2015 Financial Results and Recent Activities BOSTON, MA
ZIOPHARM Reports Third-Quarter 2015 Financial Results and Recent Activities BOSTON, MA November 2, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the third quarter ended September 30, 2015, and provided an update on the company s recent activi
Read more →TCRTIntrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease Companies Form New Collaboration to Pursue Cellular Therapy Approaches to Autoimmune Disorder Companies to Host Conference Call
Intrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease Companies Form New Collaboration to Pursue Cellular Therapy Approaches to Autoimmune Disorder Companies to Host Conference Call and Webcast Slide Presentation Today at 5:00 PM ET Germa
Read more →TCRTZIOPHARM Appoints Scott Tarriff to Its Board of Directors BOSTON
ZIOPHARM Appoints Scott Tarriff to Its Board of Directors BOSTON, September 28, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer immunotherapies, today announced the appointment of Scott Tarr
Read more →TCRTForward looking Statements This presentation contains certain forward looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward looking statements provided by the Pri
Cancer Res. 2015 Sep 1;75(17):3505 18. PMID: 26330164 Extensive Data Outreach 27 CRI CIMT EATI AACR Immunotherapy Conference September 16 19, NY, NY SITC November 4 8, National Harbor , MD SNO November 19 23, San Antonio, TX CAR T Summit November 12 13, Boston, MA ASH December 5
Read more →TCRTZIOPHARM Reports Second-Quarter 2015 Financial Results and Recent Activities BOSTON, MA
ZIOPHARM Reports Second-Quarter 2015 Financial Results and Recent Activities BOSTON, MA August 10, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the second quarter ended June 30, 2015, and provided an update on the company s recent activities
Read more →TCRTThis presentation contains certain forward looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform
Chimeric Antigen Receptor (CAR+) T cells: Target cell surface tumor associated antigens (TAAs) independent of HLA Public antigens 2. T Cell Receptor (TCR + ) cells: Target intracellular TAAs dependent on HLA Private antigens 3. Natural Killer (NK) cells: Target tumor with loss of
Read more →TCRTZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer BOSTON
ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer BOSTON, June 2, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that C
Read more →TCRTZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities BOSTON, MA
ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities BOSTON, MA May 7, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company s recent activities. Th
Read more →TCRTZIOPHARM Appoints Laurence J. N. Cooper, M.D., Ph.D., Chief Executive Officer BOSTON, MA
ZIOPHARM Appoints Laurence J. N. Cooper, M.D., Ph.D., Chief Executive Officer May 7, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the appointment of Laurence J. N. Cooper, M.D., Ph.D., to the role of Chief Executive Officer, effective immediately. Dr. Cooper brin
Read more →TCRTZIOPHARM Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12
ZIOPHARM Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients with Locally Advanced or Metastatic Breast Cancer BOSTON, April 27, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercializat
Read more →TCRTZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened through Collaboration with Merck Serono BOSTON, MA and GERMANTOWN, MD
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened through Collaboration with Merck Serono BOSTON, MA and GERMANTOWN, MD, March 30, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) and Intrexon Corporation (NYSE: XON) today announced their oncology programs will be st
Read more →TCRTZIOPHARM Reports Fourth-Quarter and Full-Year 2014 Financial Results and Recent Activities BOSTON, MA
ZIOPHARM Reports Fourth-Quarter and Full-Year 2014 Financial Results and Recent Activities BOSTON, MA February 26, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2014, and provided an update
Read more →TCRTZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares BOSTON, February 12, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full the
Read more →TCRTZIOPHARM Oncology Announces Pricing of Public Offering of Common Stock
ZIOPHARM Oncology Announces Pricing of Public Offering of Common Stock BOSTON, February 3, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that it has priced its previously announced underwritten public offering of common stock consisting of 10,000,000 shares at a p
Read more →TCRTZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock BOSTON, February 2, 2015 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that it intends to commence an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares in th
Read more →TCRTThe Future of Cancer Therapy JP Morgan 33rd Annual Healthcare Conference January2015 www.ziopharm. com Forward_Looking Statements This presentation _ forward contains certain looking information about ZIOPHARM Oncology t
The Future of Cancer Therapy 33rd Annual Healthcare Conference Forward_Looking Statements _ forward contains certain looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for forward Forward looking statements provided by the Private Se
Read more →TCRTIntrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Com
Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies
Read more →TCRTZIOPHARM and Intrexon Present Clinical and Preclinical Data from Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting BOSTON, Ma. and GERMANTOWN, Md.
ZIOPHARM and Intrexon Present Clinical and Preclinical Data from Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting BOSTON, Ma. and GERMANTOWN, Md. December 3, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the deve
Read more →TCRTZIOPHARM Reports Third-Quarter 2014 Financial Results Provides Overview of Activities BOSTON, MA
ZIOPHARM Reports Third-Quarter 2014 Financial Results Provides Overview of Activities BOSTON, MA October 30, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the third quarter ended September 30, 2014, and provided an update on the company s pr
Read more →TCRTZIOPHARM Reports Second-Quarter 2014 Financial Results and Reviews Recent Activities BOSTON, MA
ZIOPHARM Reports Second-Quarter 2014 Financial Results and Reviews Recent Activities August 7, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the second quarter ended June 30, 2014, and provided an update on the company s product development a
Read more →TCRTZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin
ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin BOSTON and TOKYO (July 31, 2014) ZIOPHARM Oncology, Inc. ( ZIOPHARM ) (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new ca
Read more →TCRTZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated with Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting BOSTON, MA
ZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated with Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting BOSTON, MA May 22, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development an
Read more →TCRTZIOPHARM Reports First-Quarter 2014 Financial Results and Reviews Recent Activities BOSTON, MA
ZIOPHARM Reports First-Quarter 2014 Financial Results and Reviews Recent Activities May 8, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2014, and provided an update on the company s product development activ
Read more →TCRTZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer
ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer NEW YORK, NY April 8, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cance
Read more →TCRTZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities BOSTON, MA
ZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities BOSTON, MA March 3, 2014 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an upda
Read more →TCRTThe Future of Cancer Therapy BIO CEO & Investor Conference February 2014 www.ziopharm.com Forward-Looking Statements This presentation contains certain forward-looking information about ZIOPHARM Oncology that is intended
The Future of Cancer Therapy BIO CEO & Investor Conference Forward-Looking Statements contains certain forward-looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litiga
Read more →TCRTZIOPHARM Reports Positive Interim Results in Patients with Advanced Melanoma from Ongoing Phase 1/2 Study of Ad-RTS-IL-12 Potent biological activity observed in injected and non-injected lesions Findings presented at Mel
ZIOPHARM Reports Positive Interim Results in Patients with Advanced Melanoma from Ongoing Phase 1/2 Study of Ad-RTS-IL-12 Potent biological activity observed in injected and non-injected lesions Findings presented at Melanoma Bridge 2013 Conference Conference Call Scheduled f
Read more →TCRTZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects with Recurrent or Progressive Glioblastoma BOSTON
ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects with Recurrent or Progressive Glioblastoma BOSTON, December 6, 2013 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the unanimous approval of the
Read more →TCRTZIOPHARM Oncology Prices Public Offering of Common Stock
ZIOPHARM Oncology Prices Public Offering of Common Stock BOSTON, Oct. 24, 2013 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the pricing of its previously announced public offering of 14,300,000 shares of its common stock at a public offering price of $3.50 per share.
Read more →TCRTMesoblast, Intrexon and ZIOPHARM to Target Cancers Partnership Combines Mesoblast s Cell and Intrexon s Transgene Technologies Melbourne, Australia; Germantown, MD and Boston, MA, USA
Mesoblast, Intrexon and ZIOPHARM to Target Cancers Partnership Combines Mesoblast s Cell and Intrexon s Transgene Technologies Melbourne, Australia; Germantown, MD and Boston, MA, USA; October 23, 2013 Mesoblast Limited (ASX: MSB), a world leader in the development of cell-bas
Read more →TCRTZIOPHARM Announces Third Quarter Financial Results and Updates Key Development Activities BOSTON, MA
ZIOPHARM Announces Third Quarter Financial Results and Updates Key Development Activities BOSTON, MA October 22, 2013 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the third quarter ended September 30, 2013, and provided an update on the Company s
Read more →TCRTZIOPHARM and Intrexon Announce Presentation of Data Highlighting Regulated Gene Expression System in Tumor-Homing Mesenchymal Stem Cells Results Presented at the 2013 AACR-NCI-EORTC International Conference on Molecular
ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Regulated Gene Expression System in Tumor-Homing Mesenchymal Stem Cells Results Presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and BOSTON, MA Oct. 22, 2013 ZIOPHARM Oncology, I
Read more →TCRTSeptember 2013 Forward Looking Statements This presentation contains certain forward looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for forward looking statements provided b
Clinical stage synthetic biology cancer company 2. We believe we are the farthest advanced at regulating gene function in vivo in humans, regulating gene expression, and titrating levels of expression 3. Lead clinical program is Ad RTS IL 12 4. We have multiple novel programs dri
Read more →TCRTZIOPHARM Announces Second Quarter Financial Results and Updates Key Development Activities Advances Synthetic Biology Platform with Channel Collaborator Intrexon Corporation BOSTON, MA
ZIOPHARM Announces Second Quarter Financial Results and Updates Key Development Activities Advances Synthetic Biology Platform with Channel Collaborator Intrexon Corporation BOSTON, MA August 8, 2013 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results f
Read more →TCRTZIOPHARM Announces First Quarter Financial Results and Key Developments Highlights Include Initiation of Phase 2 Study of Ad-RTS-IL-12 in Advanced Breast Cancer BOSTON, MA
ZIOPHARM Announces First Quarter Financial Results and Key Highlights Include Initiation of Phase 2 Study of Ad-RTS-IL-12 in Advanced BOSTON, MA May 7, 2013 ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2013, and
Read more →TCRTZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma Restructuring to Place Exclusive Strategic Focus on Synthetic Biology Programs Company to Host Conference Call Today
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma Restructuring to Place Exclusive Strategic Focus on Synthetic Biology Programs Company to Host Conference Call Today, March 26, 2013 at 8:30 AM ET YORK, NY March, 26, 2013 ZIOPHARM Oncology, In
Read more →TCRTPhase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events -Results Will be Announced Last Week of March
Phase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events -Results Will be Announced Last Week NEW YORK, NY - February 12, 2013 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that
Read more →TCRTINDEMNITY AGREEMENT This Indemnity Agreement (this " Agreement ") dated as of __________ ___, 2012, is made by and between ZIOPHARM Oncology, Inc. , a Delaware corporation (the " Company "), and __________ (" Indemnitee
Indemnity Agreement (this "Agreement") dated as of __________ ___, 2012, is made by and between ZIOPHARM Oncology, Inc., a Delaware corporation (the "Company"), and __________ ("Indemnitee"). Company desires to attract and retain the services of highly qualified individuals as
Read more →TCRTZIOPHARM Announces Third Quarter Financial Results and Key Developments Highlights Include Initiation of Phase 2 Study of Ad-RTS IL-12 in Advanced Melanoma
ZIOPHARM Announces Third Quarter Financial Results and Key Developments Highlights Include Initiation of Phase 2 Study of Ad-RTS IL-12 in Advanced Melanoma NEW YORK, NY - November 8, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the thir
Read more →TCRTZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase NEW YORK, NY - October 25, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercializati
Read more →TCRTZIOPHARM Issues Statement Regarding Misleading Blog Post
ZIOPHARM Issues Statement Regarding Misleading NEW YORK, NY - October 19, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today issued the following statement regarding a blog entry posted by Richard Pearson, Contributor, on Forbes.com: "The statements made in Mr. Pearson's bl
Read more →TCRTBetter Cancer Medicine 19 th Annual NewsMakers in the Biotech Industry Conference Forward - Looking Statements This presentation contains certain forward - looking information about ZIOPHARM Oncology that is intended to
Better Cancer Medicine 19 th Annual NewsMakers in the Biotech Industry Conference Forward - Looking Statements This presentation contains certain forward - looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for "forward - looking statem
Read more →TCRTZIOPHARM Announces Second Quarter Financial Results and Key Developments Highlights Include Completion of Enrollment in PICASSO 3 Trial for Soft Tissue Sarcoma and Initiation of MATISSE Study for Small Cell Lung Cancer
ZIOPHARM Announces Second Quarter Financial Results and Key Developments Highlights Include Completion of Enrollment in PICASSO 3 Trial for Soft Tissue Sarcoma and Initiation of MATISSE Study for Small Cell Lung Cancer NEW YORK, NY - August 2, 2012 - ZIOPHARM Oncology, Inc.
Read more →TCRTZIOPHARM Oncology Announces New Executive Team
ZIOPHARM Oncology Announces New Executive NEW YORK, NY - July 16, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a new executive leadership team reporting to J
Read more →TCRTJonathan Lewis, MD, PhD Chief Executive Officer 2012 Research & Development Day
Jonathan Lewis, MD, PhD Chief Executive Officer 2012 Research & Development Day June 19, 2012 Forward - Looking Statements This presentation contains certain forward - looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for "forward - lo
Read more →TCRTZIOPHARM Oncology Completes Enrollment in PICASSO 3 Trial Evaluating Palifosfamide in Front-Line Metastatic Soft Tissue Sarcoma
ZIOPHARM Oncology Completes Enrollment in PICASSO 3 Trial Evaluating Palifosfamide in Front-Line Metastatic Soft Tissue Sarcoma NEW YORK, NY - June 2, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization o
Read more →TCRTZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer -Brings Corporate Strategy, Transaction and Finance Background to ZIOPHARM
ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer -Brings Corporate Strategy, Transaction and Finance Background to ZIOPHARM- NEW YORK, NY - May 8, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) a biopharmaceutical company with
Read more →TCRTZIOPHARM Reports First Quarter Financial Results
ZIOPHARM Reports First Quarter Financial NEW YORK, NY - May 3, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today its financial results for the first quarter ended March 31, 2012, and provided an update on the Company's activities. The Company's cash used in operat
Read more →TCRTZIOPHARM Oncology Presents Compelling Data Showing Palifosfamide Activity in Breast Cancer Models at AACR Meeting Company to Explore Proof-of-Concept Clinical Study in Breast Cancer in the Second Half of 2012 CHICAGO
ZIOPHARM Oncology Presents Compelling Data Showing Palifosfamide Activity in Breast Cancer Models at AACR Meeting Company to Explore Proof-of-Concept Clinical Study in Breast Cancer in the Second Half of 2012 CHICAGO - April 3, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP),
Read more →TCRTZIOPHARM Oncology Presents Preclinical Data at AACR Meeting Demonstrating Significant Anti-Tumor Activity with Two Immunotherapies Expressed In Vivo by a Regulated Gene System Program Committee Recognizes Presentation as
ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting Demonstrating Significant Anti-Tumor Activity with Two Immunotherapies Expressed In Vivo by a Regulated Program Committee Recognizes Presentation as Among the Best Science at AACR CHICAGO - April 2, 2012 - ZIOPHARM
Read more →TCRTZIOPHARM Oncology Provides Update on PICASSO 3 Trial Highly Rigorous Progression-free Survival Trial Approaches 90% Completion PFS Data Expected 2H 2012
ZIOPHARM Oncology Provides Update on PICASSO Highly Rigorous Progression-free Survival Trial Approaches 90% Completion PFS Data Expected 2H 2012 NEW YORK - April 2, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company with small molecule and synthetic bi
Read more →TCRTZIOPHARM Reports Fourth Quarter and Full Year 2011 Financial Results --Significant Progress for Lead Programs
ZIOPHARM Reports Fourth Quarter and Full Year 2011 Financial Results --Significant Progress for Lead Programs-- NEW YORK, NY - February 29, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today its financial results for the fourth quarter and full year ending December
Read more →TCRTZIOPHARM Oncology Reports Positive Preliminary Palifosfamide Overall Survival Data from Randomized Phase 2 Study in Soft Tissue Sarcoma
ZIOPHARM Oncology Reports Positive Preliminary Palifosfamide Overall Survival Data from Randomized Phase 2 Study in Soft Tissue Sarcoma NEW YORK, NY - February 13, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company with small molecule and synthetic biol
Read more →TCRTZIOPHARM Oncology Announces Proposed Public Offering of Common Stock New York, NY
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock New York, NY - January 19, 2012 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that it intends to commence an underwritten public offering of shares of its common stock. All of the shares in the propo
Read more →TCRTth Annual J.P. Morgan Healthcare Conference Jonathan Lewis, MD, PhD Chief Executive Officer Better Cancer Medicine Forward - Looking Statements This presentation contains certain forward - looking information about ZIOPH
30 th Annual J.P. Morgan Healthcare Conference Jonathan Lewis, MD, PhD Chief Executive Officer Better Cancer Medicine Forward - Looking Statements This presentation contains certain forward - looking information about ZIOPHARM Oncology that is intended to be covered by the safe
Read more →TCRTZIOPHARM Granted European Patent Allowance for Palifosfamide --Additional Patent Issuance for Darinaparsin
ZIOPHARM Granted European Patent Allowance for Palifosfamide --Additional Patent Issuance for Darinaparsin-- NEW YORK, NY - December 7, 2011 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has received an allowance from the European Patent Office for Patent App
Read more →TCRTZIOPHARM Oncology Presents Preclinical Data for Darinaparsin Effect on Hedgehog Signaling Pathway in Prostate Cancer at AACR-NCI-EORTC Meeting
ZIOPHARM Oncology Presents Preclinical Data for Darinaparsin Effect on Hedgehog Signaling Pathway in Prostate Cancer at AACR-NCI-EORTC Meeting NEW YORK, NY - November 13, 2011 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synth
Read more →TCRTZIOPHARM Reports Third Quarter Financial Results and Highlights Ends quarter with $119 million in cash and cash equivalents
ZIOPHARM Reports Third Quarter Financial Results and Highlights Ends quarter with $119 million in cash and cash equivalents NEW YORK, NY - November 3, 2011 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approa
Read more →TCRTZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting NEW YORK, NY (
ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting NEW YORK, NY (October 28, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approa
Read more →TCRTZIOPHARM Reports Second Quarter Financial Results and Highlights Ends quarter with $130 million in cash and cash equivalents
ZIOPHARM Reports Second Quarter Financial Results and Highlights Ends quarter with $130 million in cash and cash equivalents NEW YORK, NY - August 1, 2011 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approac
Read more →TCRTZIOPHARM Oncology Announces Acceptance of Investigational New Drug Application for ZIN ATI-001 (Ad-RTS-IL-12), a Novel DNA-Based Oncology Therapeutic Candidate NEW YORK, NY (
ZIOPHARM Oncology Announces Acceptance of Investigational New Drug Application for ZIN ATI-001 (Ad-RTS-IL-12), a Novel DNA-Based Oncology Therapeutic Candidate NEW YORK, NY (June 10, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molec
Read more →TCRTZIOPHARM Announces Initial Positive Data Presented at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans Treatment with ZIN-CTI-001 Well
ZIOPHARM Announces Initial Positive Data Presented at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans Treatment with ZIN-CTI-001 Well Tolerated, Demonstrates Substantial Disease Control Intra-
Read more →TCRTZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity Human Application of Novel, Synthetic Biology Approach t
ZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity Human Application of Novel, Synthetic Biology Approach to be Presented at 2011 ASCO Annual Meeting SEATTLE, WA (Ma
Read more →TCRTZIOPHARM Oncology to Present Data at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans --Abstracts Released on ASCO.org-- NEW YORK--(BUS
ZIOPHARM Oncology to Present Data at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans --Abstracts Released on ASCO.org-- NEW YORK--(BUSINESS WIRE)-- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), anno
Read more →TCRTZIOPHARM Oncology Files Investigational New Drug Application for Ad-RTS-IL-12, a Novel DNA-Based Oncology Therapeutic Candidate NEW YORK, NY (
ZIOPHARM Oncology Files Investigational New Drug Application for Ad-RTS-IL-12, a Novel DNA-Based Oncology Therapeutic Candidate NEW YORK, NY (May 13, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approa
Read more →TCRTZIOPHARM Reports First Quarter Financial Results and Highlights Ends quarter with $ 124 million in cash and cash equivalents
ZIOPHARM Reports First Quarter Financial Results and Highlights Ends quarter with $ 124 million in cash and cash equivalents NEW YORK, NY - May 5, 2011 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), an oncology small molecule and synthetic biology drug development company, today rep
Read more →TCRTZIOPHARM Reports Fourth Quarter and Full Year 2010 Financial Results NEW YORK, NY (
ZIOPHARM Reports Fourth Quarter and Full Year 2010 Financial Results NEW YORK, NY (March 1, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today its financial results for the fourth quarter and full year 2010, and the filing of its Annual Report on Form 10-K with the
Read more →TCRTZIOPHARM ANNOUNCES FULL EXERCISE OF UNDERWRITER'S OPTION
ANNOUNCES FULL EXERCISE OF UNDERWRITER'S OPTION; COMPLETION OF PUBLIC NEW YORK, NY - February 8, 2011 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the completion of its previously announced public offering of 9,600,000 shares of common stock. In connection with th
Read more →TCRTZIOPHARM
PRICES PUBLIC OFFERING OF COMMON STOCK NEW YORK, NY - February 3, 2011 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.75 per share. The public offer
Read more →TCRTANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK NEW YORK, NY - February 2, 2011 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced that it is offering to sell 9,600,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritte
Read more →TCRTZIOPHARM Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency NEW YORK, NY (
Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency NEW YORK, NY (January 20, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicine
Read more →TCRTZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics RJ Kirk, CEO and Chairman of Intrexon, to Join ZIOPHARM Board of Directors NEW YORK, NY and GERMANTOWN,
Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics Kirk, CEO and Chairman of Intrexon, to Join ZIOPHARM Board of NEW YORK, NY and GERMANTOWN, MD (January 6, 2011) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a small molecu
Read more →TCRTZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of Palifosfamide in Small Cell Lung and Other Cancers NEW YORK, NY (
Oncology Announces First Patient Dosed in Phase I Study of in Small Cell Lung and Other Cancers NEW YORK, NY (December 29, 2010) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at
Read more →TCRTZIOPHARM Granted Japanese Patent for Darinaparsin New York, NY - September 27 , 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, wit
Granted Japanese Patent for Darinaparsin New York, NY - September 27, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral form
Read more →TCRTZIOPHARM Receives FDA Orphan Drug Designation for Darinaparsin in the Treatment of Peripheral T-cell Lymphoma NEW YORK, NY (
Receives FDA Orphan Drug Designation for Darinaparsin in the Treatment of Peripheral T-cell Lymphoma NEW YORK, NY (September 23, 2010) - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Desi
Read more →TCRTZIOPHARM Announces Initiation of Palifosfamide Pivotal Study -- Front-Line Therapy Trial for Patients with Metastatic Soft Tissue Sarcoma -- Company to Host Conference Call and Webcast with Outside Experts on Tuesday, Ju
Announces Initiation of Palifosfamide Pivotal Study Front-Line Therapy Trial for Patients with Metastatic Soft Tissue Sarcoma to Host Conference Call and Webcast with Outside Experts Tuesday, July 20th at 8:00 NEW YORK, NY (July 19, 2010) - ZIOPHARM Oncology, Inc. (Nasdaq: Z
Read more →TCRTZIOPHARM Provides Guidance on Planned Pivotal Phase III Study of Palifosfamide in Metastatic Soft Tissue Sarcoma New York, NY
Provides Guidance on Planned Pivotal Phase III Study Palifosfamide in Metastatic Soft Tissue Sarcoma New York, NY - June 21, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in met
Read more →TCRTZIOPHARM Presents Positive Palifosfamide PICASSO Phase II Results in Oral Session at ASCO -- Randomized Phase III Expected to Commence Mid-Year -- New York, NY
Presents Positive Palifosfamide PICASSO II Results in Oral Session at ASCO Randomized Phase III Expected to Commence Mid-Year -- New York, NY - June 7, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire Verschraegen of the University of New Mexico,
Read more →TCRTZIOPHARM announces proposed public offering of common stock
announces proposed public offering of common stock NEW YORK, NY - May 26, 2010 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole b
Read more →TCRTZIOPHARM to Present Further Palifosfamide PICASSO Phase II Results in Oral Session at ASCO -- Abstracts Released on ASCO.org -- New York, NY
to Present Further Palifosfamide PICASSO Phase II Results Oral Session at ASCO Abstracts Released on ASCO.org -- New York, NY - May 21, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, le
Read more →TCRTZIOPHARM REPORTS FIRST QUARTER FINANCIAL RESULTS -- Decreased Cash Burn from Operations, Continued Clinical Progress
REPORTS FIRST QUARTER FINANCIAL RESULTS Decreased Cash Burn from Operations, Continued Clinical Progress -- NEW YORK, NY - April 30, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensiti
Read more →TCRTZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors -- Dr. Murray Brennan Named Chairman of Board -- NEW YORK , NY - April 6 , 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), anno
Elects George B. Abercrombie, former CEO of Roche, to Board of Directors Dr. Murray Brennan Named Chairman of Board -- NEW YORK, NY - April 6, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today the appointment of George B. Abercrombie to its Board of Directors. M
Read more →TCRTZIOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2009
REPORTS FOURTH QUARTER AND YEAR 2009 FINANCIAL RESULTS NEW YORK, NY - March 17, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing
Read more →TCRTZIOPHARM RECEIVES IMPORTANT PALIFOSFAMIDE U.S. PATENT ALLOWANCE -- Additional Patent Issuances for Darinaparsin and Indibulin -- New York, NY
RECEIVES IMPORTANT PALIFOSFAMIDE U.S. PATENT ALLOWANCE Additional Patent Issuances for Darinaparsin and Indibulin -- New York, NY - January 26, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has received a Notice of Allowance from the U.S. Patent and Tr
Read more →Competitive Position
How TCRT ranks across every disease it competes inCompetitive Position is a premium feature
See how TCRT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial